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Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the progno-
sis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients
with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination
with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab
and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric can-
cer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-
controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab
or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with
advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
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Gastric cancer is the fifth most common cancer in the world and the third-leading cause of cancer-related death [1].
More than 1 million new cases were diagnosed in 2018, and 780,000 people died of the disease. The incidence of
gastric cancer is substantially higher in Eastern Asia than in any other region, and it is diagnosed twice as frequently
in men. Although often considered a single entity, gastric cancers can be divided into noncardia gastric cancer,
arising from the distal portion of the stomach, and cardia gastric cancer, which includes cancers of the upper
stomach and the gastroesophageal junction (GEJ) [2]. The primary risk factor for the development of noncardia
gastric cancer is the presence of Helicobacter pylori, which is believed to be causative in almost 90% of cases [3]. In
contrast, cardia gastric cancers are more frequently associated with obesity and gastroesophageal reflux disease [2].
In addition to their topographic categorization, gastric cancers can be divided into one of four molecular
subtypes, each associated with specific genomic and prognostic characteristics [4,5]. Of note, this molecular profiling
has enabled the identification of potentially targetable alterations in gastric cancer and provides an opportunity
to identify biomarkers of response. The most common of these subtypes is the chromosomally unstable tumors
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(CIN) subtype, which accounts for approximately 50% of all gastric cancers [4]. This subtype is associated with
intestinal type histology, elevated frequency in GEJ/cardia gastric cancer, TP53 mutation and amplification of
receptor tyrosine kinases, including HER2 [4,6]. Consequently, HER2 overexpression is observed in 10–22% of all
gastric cancers [6,7].
Surgical resection can be curative for patients with early-stage gastric cancer; however, because of the largely
asymptomatic nature and aggressiveness of the disease at this stage, most diagnoses are made when the disease
is advanced [7,8]. The prognosis for patients with advanced-stage gastric cancer is poor, with survival ranging
from approximately 4 months with best supportive care to 12 months with chemotherapy [8]. The recommended
first-line treatment for most patients with advanced gastric cancer is doublet combination therapy with plat-
inum and fluoropyrimidine [7,9]. For patients with HER2-postive disease, the recommended first-line regimen
is trastuzumab (anti-HER2) in combination with platinum and fluoropyrimidine-based chemotherapy [7,9]. The
inclusion of trastuzumab in the treatment regimen for gastric cancer was based on the results of the Phase III
ToGA trial (ClinicalTrials.gov: NCT01041404), which showed that the addition of trastuzumab to a regimen
of capecitabine + cisplatin or fluorouracil + cisplatin improved overall survival (OS) from 11.1 to 13.8 months
(hazard ratio [HR], 0.74; 95% CI: 0.60–0.91; p = 0.0048) and progression-free survival (PFS) from 5.5 to 6.7
months (HR: 0.71; 95% CI: 0.59–0.85; p = 0.0002) in patients with HER2-positive gastric or GEJ cancer [10].
First-line treatment combinations with pertuzumab (anti-HER2) plus trastuzumab plus chemotherapy as well
as lapatinib (tyrosine kinase inhibitor) plus chemotherapy versus placebo plus chemotherapy have not proven
successful in Phase III trials thus far because of their failure to meet the primary end point in the JACOB and
TRIO-013/LOGiC trials, respectively [11,12].
The choice of second-line or later therapy for patients with advanced gastric cancer is dependent on therapy
previously received and on performance status [9]. The continuation of HER2 inhibitors after disease progression
with trastuzumab has not been shown to be effective in prospective trials [13]. Recommended chemotherapy-based
regimens include docetaxel, paclitaxel or irinotecan monotherapy; fluorouracil + irinotecan; and trifluridine and
tipiracil (third-line or later therapy) [9]. The anti-vascular endothelial growth factor receptor 2 antibody ramucirumab
in combination with paclitaxel is also recommended for use as second-line therapy based on the results of the Phase
III RAINBOW trial (NCT01170663), which demonstrated improved survival with this combination compared
with paclitaxel alone (median OS: 9.6 vs 7.4 months; HR: 0.807; 95% CI: 0.678–0.962; p = 0.017) [9,14].
Pembrolizumab, an anti-PD-1 monoclonal antibody, is recommended by the National Comprehensive Cancer
Network as the preferred second-line therapy for patients with microsatellite instability-high (MSI-H) or mismatch
repair deficient tumors and as a third-line therapy for patients with PD-L1–positive (combined positive score [CPS]
≥1) tumors [9]. The anti-PD-1 monoclonal antibody nivolumab is recommended by the Japanese Gastric Cancer
Association as third-line therapy [15]. Of note, PD-1/PD-L1 inhibitors have not yet been approved by the EMA
for use in patients with gastric cancer.
Given the limited survival benefit observed with currently recommended therapies, there remains a need for
novel therapeutic regimens for the treatment of patients with advanced gastric cancer.
KEYNOTE-811 trial
Here we describe the design and rationale of the randomized, double-blind, placebo-controlled, Phase III
KEYNOTE-811 study (NCT03615326), which will evaluate the efficacy and safety of pembrolizumab or placebo in
combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive
gastric or GEJ adenocarcinoma.
Background & rationale
The PD-1/PD-L1 pathway is an important regulatory component of the immune response and plays a critical
role in tumor evasion of immune surveillance [16]. A growing body of evidence indicates that PD-1 and PD-L1 are
frequently overexpressed in gastric cancer and that their upregulation may be prognostic of poor outcome [17,18].
Consequently, PD-1 and PD-L1 represent promising targets for the treatment of gastric cancer.
Pembrolizumab is a highly selective, humanized, monoclonal immunoglobulin G4-κ antibody that binds to
PD-1 and blocks its interactions with PD-L1 and PD-L2, thereby releasing PD-1 pathway-mediated inhibition
of the antitumor immune response [19]. Pembrolizumab has demonstrated durable antitumor activity in patients
with gastric cancer in several trials. In the Phase Ib KEYNOTE-012 study (NCT01848834), eight of 36 evaluable
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patients in the gastric cancer cohort achieved partial response (PR) with pembrolizumab monotherapy, for an
objective response rate (ORR) of 22% (95% CI: 10–39) [20]. A clinically meaningful result was also observed in
cohort 1 of the Phase II KEYNOTE-059 study (NCT02335411), which investigated the efficacy of third-line or
later pembrolizumab monotherapy in patients with gastric or GEJ cancer [21]. Of 259 patients enrolled in this
cohort, 30 patients (12%; 95% CI: 8–16) experienced objective response; six of those patients (2%; 95% CI:
1–5) achieved complete response (CR). The median OS in this cohort was 5.6 months. The potential benefit
of pembrolizumab for the treatment of gastric cancer was also investigated in the Phase III KEYNOTE-061
trial (NCT02370498), which evaluated the efficacy of pembrolizumab monotherapy compared with paclitaxel
in patients with advanced gastric or GEJ cancer that had progressed on first-line chemotherapy with platinum
and fluoropyrimidine [22]. After follow-up of 7.9 months, the median OS in patients with CPS ≥1 tumors – 9.1
months for pembrolizumab and 8.3 months for paclitaxel (HR: 0.82; 95% CI: 0.66–1.03; one-sided p = 0.0421) –
was not significantly different between the groups. PFS and ORR were similar between the treatment groups,
but responses were more durable in patients who received pembrolizumab than those who received paclitaxel
(median duration of response [DOR]: 18.0 vs 5.2 months, respectively). Post hoc analyses of patients with CPS
≥10 tumors revealed a greater survival benefit for the pembrolizumab group than the paclitaxel group (HR: 0.64;
95% CI: 0.41–1.02) [23]. In the Phase III KEYNOTE-062 study (NCT02494583), first-line pembrolizumab or
pembrolizumab + chemotherapy versus chemotherapy was evaluated in patients with CPS ≥1, HER2-negative,
advanced gastric cancer [24]. Pembrolizumab monotherapy was noninferior to chemotherapy for OS in patients
with CPS ≥1 tumors but resulted in a clinically meaningfully improvement for OS in patients with CPS ≥10
tumors (HR: 0.69; 95% CI: 0.49–0.97). Pembrolizumab + chemotherapy did not show superior OS and PFS in
patients with CPS ≥1 tumors and OS in patients with CPS ≥10 tumors. The KEYNOTE-059 study included two
additional gastric cancer cohorts in its investigation of pembrolizumab as monotherapy or in combination with
chemotherapy in previously untreated patients [25]. The ORR among patients who received first-line pembrolizumab
monotherapy was 26% (95% CI: 12–45; eight of 31 patients; 2 CR), and the median OS was 20.7 months. In
patients who received first-line pembrolizumab in combination with a fluoropyrimidine and a cisplatin, the ORR
was 60% (95% CI: 39–79; 15 of 25 patients; 1 CR) and the median OS was 13.8 months.
These data demonstrate that pembrolizumab has durable clinical benefit in patients with advanced gastric cancer
and shows promise when used in combination with chemotherapy. However, for patients with HER2-positive
disease, the current standard of care also includes treatment with the HER2-targeted antibody trastuzumab [7,9]. In
recent years, there has been growing interest in the use of trastuzumab in combination with immune checkpoint
inhibitors because of observations that the immune system substantially contributes to the therapeutic effects of
HER2-targeted antibodies and that treatment with trastuzumab may increase tumor expression of PD-L1 [26,27].
The combination of trastuzumab and pembrolizumab was initially investigated in the Phase Ib/II PANACEA
trial (NCT02129556) in patients with trastuzumab-resistant advanced HER2-positive breast cancer [28]. Results
indicated that the combination had manageable safety and durable clinical benefit, but only in patients with
PD-L1-positive (CPS ≥1) tumors. This study established proof of concept for this dual antibody approach, but
the efficacy of these agents in combination with chemotherapy has not yet been established. Two early-phase trials
(NCT02954536 and NCT02901301) are underway to investigate the combination of pembrolizumab, trastuzumab
and chemotherapy for the treatment of gastric or GEJ cancer; both studies enrolled patients regardless of PD-L1
status. Additionally, these studies were not powered to distinguish differences based on PD-L1 status, although this
was explored in NCT02954536; the authors suggested that the effect was similar regardless of PD-L1 status [29].
Results from one of these trials (NCT02954536) showed that a combination of pembrolizumab, trastuzumab
and chemotherapy (oxaliplatin or cisplatin) had a manageable safety profile and promising efficacy, with an ORR
of 91% (95% CI: 78–97; 32 of 35 patients; six CRs) in patients with esophagogastric adenocarcinoma [30]. In
another trial (NCT02901301), the ORR was 77% with pembrolizumab, trastuzumab, capecitabine and cisplatin
as first-line therapy for HER-positive advanced gastric cancer [31]; the dosing schedule and patient population are
similar to those of the KEYNOTE-811 trial.
Taken together, the available evidence indicates that pembrolizumab has durable efficacy in gastric cancer and
that pembrolizumab combined with trastuzumab and chemotherapy is a promising treatment option in patients
with HER2-positive disease.
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Key eligibility criteria
Histologically or cytologically confirmed 
diagnosis of previously untreated,  
locally advanced unresectable or  
metastatic HER2-positive gastric or  
GEJ adenocarcinoma
• Measurable disease per RECIST v1.1
•
• ECOG performance status of 0 or 1 
• Adequate tissue sample
Stratification




Pembrolizumab 200 mg Q3W +
trastuzumab 8 mg/kg loading dose,
and 6 mg/kg thereafter Q3W +
investigator’s choice of FP or CAPOX 
Placebo (normal saline) Q3W +
trastuzumab 8 mg/kg loading dose,
and 6 mg/kg thereafter Q3W +
investigator’s choice of FP or CAPOX 
Pembrolizumab 200 mg Q3W +
trastuzumab 8 mg/kg loading dose,
and 6 mg/kg thereafter Q3W + SOX
Key eligibility criteria
• Histologically or cytologically confirmed 
diagnosis of previously untreated,  
locally advanced unresectable or  
metastatic HER2-positive gastric or  
GEJ adenocarcinoma
• Measurable disease per RECIST v1.1
• ECOG performance status of 0 or 1




Placebo (normal saline) Q3W +
trastuzumab 8 mg/kg loading dose,
and 6 mg/kg thereafter Q3W + SOX 
Figure 1. KEYNOTE-811 study design. (A) Global cohort. (B) Japan-specific S-1 + oxaliplatin cohort.
CAPOX: Capecitabine + oxaliplatin; FP: 5-Fluorouracil + cisplatin; R: Randomization; SOX: S-1 + oxaliplatin.
Study design
KEYNOTE-811 is an international, multicenter, randomized, double-blind, placebo-controlled, Phase III study
consisting of two cohorts (Figure 1). The global cohort will receive pembrolizumab or placebo in combination
with trastuzumab and either cisplatin + 5-fluorouracil (FP) or oxaliplatin + capecitabine (CAPOX); the Japan-
specific cohort will receive pembrolizumab or placebo in combination with trastuzumab and S-1 + oxaliplatin
(SOX). Eligible patients will be randomly assigned 1:1 to receive pembrolizumab 200 mg or placebo (normal
saline) + trastuzumab (8 mg/kg loading dose; 6 mg/kg thereafter) by intravenous infusion every 3 weeks and
investigator’s choice of FP or CAPOX in the global cohort or SOX in the Japan-specific cohort (Table 1). Treatment
will continue until confirmed disease progression, unacceptable toxicity, investigator or patient decision to withdraw
from the study, noncompliance with treatment or trial procedures, or completion of 35 cycles of study treatment
(∼2 years). Patients with progressive disease (PD) whose conditions are clinically stable may continue on treatment
at the discretion of the investigator. Patients who have attained CR may stop study treatment after receiving ≥8
doses of pembrolizumab or placebo in total and ≥2 doses after attaining confirmed CR. Patients with stable disease
(SD) or better may be eligible for an additional 17 doses of pembrolizumab if their disease progresses while they
are off study treatment provided they meet prespecified criteria.
Randomization will be performed centrally using an interactive voice/web response system. Pembrolizumab or
placebo assignment will be masked in a double-blind fashion. Patients in the global cohort will be stratified by
geographic region (Europe, Israel, North America and Australia vs Asia vs rest of world), PD-L1 status (positive
[CPS ≥1] vs negative [CPS <1]), and chemotherapy regimen (FP vs CAPOX). Patients in the Japan-specific cohort
will be stratified by PD-L1 status (positive vs negative).
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Table 1. Study treatments.
Treatment Dose Frequency Route of administration Dosing time of each 3-week cycle
Pembrolizumab 200 mg Q3W IV infusion Day 1 of each cycle
Placebo (normal saline) NA Q3W IV infusion Day 1 of each cycle
FP†
– Cisplatin‡ 80 mg/m2¶ Q3W IV infusion Day 1 of each cycle
– 5-Fluorouracil 800 mg/m2/day¶ Continuous IV infusion Days 1–5 of each cycle
CAPOX†
– Oxaliplatin 130 mg/m2¶ Q3W IV infusion Day 1 of each cycle
– Capecitabine 1000 mg/m2¶ BID Oral Days 1–14 of each cycle
SOX§
– S-1 1.25 m2; BSA: 40 mg¶
1.25 to 1.5 m2; BSA: 50 mg¶
≥1.5 m2; BSA: 60 mg¶
BID Oral Days 1–14 of each cycle
– Oxaliplatin 130 mg/m2¶ Q3W IV infusion Day 1 of each cycle
– Trastuzumab 8 mg/kg loading dose
6 mg/kg maintenance dose
Q3W IV infusion Day 1 of each cycle
†Choice of chemotherapy backbone to be decided by the investigator before randomization.
‡Duration of cisplatin treatment may be capped at 6 cycles per local country guidelines; however, treatment with 5-fluorouracil may continue per protocol.
§SOX received only by patients in the Japan-specific cohort.
¶Body surface area to be calculated per local guidance.
BID: Twice daily; CAPOX: Capecitabine + oxaliplatin; FP: 5-Fluorouracil + cisplatin; IV: Intravenous; Q3W: Every 3 weeks; SOX: S-1 + oxaliplatin.
Eligibility criteria, planned sample size & study period
Eligibility criteria are described in detail in Table 2. In brief, eligible patients are men or women aged ≥18 years
with a histologically or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or
metastatic HER2-positive gastric or GEJ adenocarcinoma. The planned sample size is approximately 692 patients
in the global cohort and 40 patients in the Japan-specific cohort, for a total of 732 patients. The estimated time
after the first participant is randomly assigned to the time of the final analysis is approximately 56 months. The
study started in October 2018, and the estimated completion date is 20 March 2024.
Study end points
The primary end points are PFS and OS. PFS is defined as the time from randomization to the first documented
disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded
independent central review (BICR) or death from any cause, whichever occurs first. OS is defined as the time from
randomization to death from any cause.
Secondary end points are ORR and DOR, per RECIST v1.1 by BICR and safety. DOR is defined as the time
from first response (CR or PR) to subsequent disease progression or death from any cause, whichever occurs first.
Exploratory end points include health-related quality of life (HRQOL; assessed using the European Organization
for the Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire core 30 items [QLQ C30]
and the gastric cancer module [STO22]), characterization of utilities (assessed using the EuroQol 5D 5-level [EQ-
5D-5L] questionnaire), molecular biomarkers and PFS and ORR per immune-related RECIST by investigator
review.
Study procedures
Disease progression and tumor response will be assessed using computed tomography (CT) or, if CT is contraindi-
cated, magnetic resonance imaging (MRI). Initial imaging will be performed within 28 days before randomization.
The first on-study imaging assessment will be performed 6 weeks after randomization, and subsequent imaging will
be performed every 6 weeks (or more frequently if clinically indicated). Imaging will continue until confirmation
of progressive disease by BICR, initiation of new anticancer treatment, withdrawal of consent or death. Response
will be confirmed by repeat imaging ≥4 weeks after the first documentation of response. Patients who experience
disease progression or start new anticancer therapy will be followed up for survival status by telephone every 12
weeks until death, withdrawal of consent, or end of study, whichever occurs first.
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Table 2. Eligibility criteria.
Inclusion criteria Exclusion criteria
• Male or female
• Age ≥18 years
• Previously untreated histologically or cytologically confirmed locally advanced
unresectable or metastatic gastric or GEJ adenocarcinoma
• HER2-positive disease, defined as either IHC 3+ or IHC 2+ in combination with
ISH+ (or FISH), as assessed by BICR on primary or metastatic tumor
• Measurable disease per RECIST v1.1 by site investigator
• Willing to use adequate contraception methods throughout the study and for 7
months after the last dose of study treatment
• ECOG PS 0 or 1
• Life expectancy ≥6 months
• Willing to provide a tumor tissue sample adequate for PD-L1 and MSI biomarker
analysis
• Adequate cardiac function, defined as left ventricular ejection fraction ≥55% as
determined by MUGA scan or ECHO and QT interval calculated according to the
Fridericia method (≤470 ms for men and ≤480 ms for women)
• Adequate hematologic function, defined as ANC ≥1500/μl, platelet count
≥100,000/μl and hemoglobin ≥9.0 g/dl or ≥5.6 mmol/l
• Adequate renal function, defined as creatinine ≤1.5 × ULN or measured or
calculated creatinine clearance ≥60 ml/min for those with creatinine levels
1.5 × ULN
• Adequate hepatic function, defined as total bilirubin ≤1.5 × ULN or direct
bilirubin ≤ULN for those with total bilirubin levels 1.5 × ULN, ALT/AST levels
≤2.5 × ULN or ≤5 × ULN for those with liver metastases, and albumin ≥2.5 g/dl
• Adequate coagulation function, defined as INR ≤1.5 × ULN, unless the patient is
receiving anticoagulant therapy with PT or aPTT/PTT is within the therapeutic
range
• Written informed consent
• Previously received neoadjuvant or adjuvant therapy for locally advanced or
metastatic disease (as long as it was completed ≥6 months before randomization
without disease progression)
• Major surgery, open biopsy or significant traumatic injury ≤28 days before
randomization, or anticipated need for major surgery during the study treatment
period
• Radiotherapy ≤14 days of randomization
• Known additional malignancy that is progressing or has necessitated active
treatment within the past 5 years (except BCC or SCC of the skin that has undergone
potentially curative treatment or in situ cervical cancer)
• Known active CNS metastases and/or carcinomatous meningitis (patients with
previously treated brain metastases may be eligible if disease is radiologically and
clinically stable)
• Active autoimmune disease that has necessitated systemic treatment (other than
replacement therapy) in the past 2 years
• Diagnosis of immunodeficiency or receiving long-term systemic steroid therapy
(≥10 mg/day prednisone equivalent) or any other form of immunosuppression
therapy within 7 days before the first dose of study treatment
• History of (noninfectious) pneumonitis treated with steroids or current
pneumonitis
• History of active tuberculosis
• Active infection necessitating systemic therapy
• Poorly controlled diarrhea
• Accumulation of pleural, ascitic or pericardial fluid necessitating drainage or
diuretic drugs ≤2 weeks before enrollment
• History or current evidence of any condition, therapy, or laboratory abnormality
that might confound the study results or interfere with study participation
• Peripheral neuropathy grade 1
• Psychiatric or substance abuse disorder that could impede cooperation with study
requirements
• Positive urine pregnancy test ≤72 h before randomization (females of
childbearing potential)
• Pregnant or breastfeeding or expecting to conceive or father children within the
projected study duration
• Active or clinically significant cardiac disease
• Known history of HIV, HBV or HCV infection
• Known hypersensitivity (grade ≥3) to any of the study drugs or their excipients
• Active infection necessitating systemic therapy
• Allogeneic tissue or solid organ transplant
• Previous treatment with anti-PD-1, anti-PD-L1 or anti-PD-L2, or with an agent
directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA4, OX40
and CD137)
• Immunized with live vaccine ≤30 days before first dose of study treatment
• Participation in study of investigational agent or device ≤4 weeks before the first
dose of study treatment
ANC: Absolute neutrophil count; aPTT: Activated partial thromboplastin time; BCC: Basal cell carcinoma; BICR: Blinded-independent central review; CNS: Central nervous system; ECHO:
Echocardiogram; ECOG: Eastern Cooperative Oncology Group; FISH: Fluorescent in-situ hybridization; GEJ: Gastroesophageal junction; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HIV:
Human immunodeficiency virus; IHC: Immunohistochemistry; INR: International normalized ratio; ISH: In-situ hybridization; MSI: Microsatellite instability; MUGA: Multigated acquisition; PT:
Prothrombin time; PTT: Partial thromboplastin time; RECIST v1.1: Response Evaluation Criteria in Solid Tumors version 1.1; SCC: Squamous cell carcinoma; ULN: Upper limit of normal.
Safety will be monitored throughout the study and for 30 days after the end of treatment (90 days for serious
adverse events and events of clinical interest). Safety analyses will include incidence, cause and outcome of adverse
events and changes in vital signs and laboratory values. Adverse events will be assessed as defined by the National
Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Patient-reported outcome assessments (QLQ-C30, QLQ-STO22 and EQ-5D-5L) will be completed by patients
electronically at cycles 1, 2, 3, 4 and 5, and every 2 cycles thereafter up to 1 year or end of treatment, whichever
comes first, and at the 30-day posttreatment follow-up visit. PD-L1 expression will be assessed using the PD-L1
IHC 22C3 pharmDx assay (Agilent Technologies, CA, USA) and measured using CPS. Additional biomarker
investigation may include genomic, metabolic and proteomic analyses.
Statistical analysis
Efficacy will be assessed in the intent-to-treat population (all randomly assigned patients) by treatment group. Safety
will be assessed in all randomly assigned patients who received ≥1 dose of study treatment according to the treatment
received. Primary hypotheses for PFS and OS will be evaluated by comparing pembrolizumab + trastuzumab and
chemotherapy with placebo + trastuzumab and chemotherapy using a stratified log-rank test. The hazard ratio will
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be estimated using a stratified Cox regression model, and event rates over time will be estimated using the Kaplan–
Meier method. ORR will be compared between treatment groups using the stratified Miettinen and Nurminen
method. The overall Type I error over the primary end points (PFS and OS) and the key secondary end point
(ORR) is strongly controlled at 2.5% (one-sided), with initially 0.2% allocated to ORR, 0.3% to PFS and 2% to
OS.
For ORR, with a sample size of approximately 260 patients at the first interim analysis, the study has approximately
90% power for detecting a 25-percentage point difference in ORR (73 vs 48%) at an initially assigned 0.002 (one-
sided) significance level. For PFS, there will be approximately 606 events at the PFS final analysis; the study has
approximately 95% power for detecting an HR of 0.7 at an initially assigned 0.003 (one-sided) significance level.
For OS, there will be approximately 551 deaths at the OS final analysis; the study has approximately 90% power
for detecting an HR of 0.75 at an initially assigned 0.020 (one-sided) significance level.
The Japan-specific cohort will be analyzed separately. Three interim analyses are planned based on projected
enrollment and event accrual rates. An external data monitoring committee will review the results of the interim
analyses to determine whether the study will continue per prespecified criteria.
Conclusion
There is promising evidence that pembrolizumab used in combination with trastuzumab + chemotherapy may
provide significant clinical benefit with manageable toxicity in patients with advanced gastric cancer. Here we
have described the methodology of the KEYNOTE-811 study, an ongoing Phase III trial designed to evaluate the
efficacy and safety of pembrolizumab in combination with trastuzumab + chemotherapy as first-line treatment for
patients with advanced HER2-positive gastric or GEJ adenocarcinoma. The study aims to show that the addition
of pembrolizumab to a regimen of trastuzumab + chemotherapy will result in improved survival compared with
treatment with trastuzumab + chemotherapy alone. It is hoped that the results of KEYNOTE-811 will further
define the role of pembrolizumab and the feasibility of a dual antibody strategy in patients with advanced gastric
cancer.
Executive summary
• Most patients with gastric cancer receive diagnoses at the advanced stage of the disease, when prognosis is poor.
• Given the limited survival benefit observed with currently recommended therapies, there remains a need for
novel therapeutic regimens to treat patients with advanced gastric cancer.
Background & rationale
• A growing body of evidence indicates that PD-1 and PD-L1 are frequently overexpressed in gastric cancer and
that their upregulation may be prognostic of poor outcome.
• Pembrolizumab has shown durable clinical benefit in patients with advanced gastric cancer and is particularly
promising when used in combination with chemotherapy.
• Combining trastuzumab and chemotherapy with pembrolizumab in the first-line setting might be beneficial for
patients with HER2-positive disease.
KEYNOTE-811 study design & eligibility criteria
• KEYNOTE-811 is an international, multicenter, randomized, double-blind, placebo-controlled, Phase III study
evaluating the efficacy and safety of pembrolizumab in combination with trastuzumab and chemotherapy as
first-line treatment of patients with advanced/metastatic HER2-positive gastric cancer.
• Eligible patients with a histologically or cytologically confirmed diagnosis of previously untreated, locally
advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma will be
randomly assigned to receive pembrolizumab or placebo in combination with trastuzumab and chemotherapy
(cisplatin + 5-fluorouacil or oxaliplatin + capecitabine [S-1 + oxaliplatin will be given in the Japan-specific
cohort]).
Outcome measures/end points
• The primary end points are progression-free survival and overall survival.
Conclusion
• It is hoped that the KEYNOTE-811 study will further define the role of pembrolizumab and the feasibility of a
dual antibody strategy in patients with advanced gastric cancer.
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Supplementary data
An infographic accompanies this paper and is included at the end of the references section in the PDF version. To view or download
this infographic in your browser please click here: www.futuremedicine.com/doi/suppl/10.2217/fon-2020-0737
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Objectives
Primary 
• Compare PFS between treatment groups
• Compare OS between treatment groups
Secondary
• Compare ORR per RECIST v1.1 by BICR between treatment groups
• Compare DOR per RECIST v1.1 by BICR between treatment groups
• Assess the safety and tolerability of pembrolizumab in combination with trastuzumab + chemotherapy
Study design and treatment including planned sample size, planned study period and study procedures
Men or women
Histologically or cytologically confirmed 
diagnosis of previously untreated, locally 
advanced unresectable or metastatic 




status of 0 or 1
Adequate tissue sample
Adequate cardiac function 
and QT interval





•  PFS (defined as the time from randomization to the first documented disease progression per RECIST v1.1 by 
   BICR or death from any cause, whichever occurs first) between treatment groups
•  OS (defined as the time from randomization to death from any cause) between treatment groups
Secondary endpoints:
•  ORR and DOR (defined as the time from first response [CR or PR] to subsequent disease progression or death 
   from any cause, whichever occurs first), per RECIST v1.1 by BICR
•  Safety  
Outcome measures/endpoints 
Exploratory endpoints:
•  HRQOL (assessed using the EORTC QLQ-C30 and EORTC QLQ-STO22)
•  
•  Molecular biomarkers
•  PFS and ORR per immune-related RECIST by investigator review
©2020 Future Medicine Ltd
GLOBAL COHORT
JAPAN COHORT
Pembrolizumab 200 mg + trastuzumab 
investigator’s choice of FP or CAPOX Q3W 
Placebo (normal saline) + trastuzumab 
investigator’s choice of FP or CAPOX Q3W 
Stratification
• Geographic region (Europe, Israel, 
North America and Australia vs 
Asia vs rest of the world 
•
 vs negative [CPS <1])
• Chemotherapy regimen
 (FP vs CAPOX)
Treatment will continue until:
• Confirmed disease progression
• Unacceptable toxicity
• Investigator or patient decision to withdraw from the study




Double-blind Placebo-controlled Phase III The planned sample 
size is ~ 692 patients 
in the global cohort 
and 40 patients in 
the Japan-specific 
cohort, for a total 
of 732 patients
Stratification
• PD-L1 status (positive 
vs negative)
Pembrolizumab 200 mg + trastuzumab 
SOX Q3W 
Placebo (normal saline) 200 mg + 
R (1:1)
R (1:1)
BICR: Blinded independent central review; CAPOX: Oxaliplatin 
+ capecitabine; CPS: Combined positive score; CR: Complete 
response; DOR: Duration of response; EORTC: European 
Organization for the Research and Treatment of Cancer; 
QLQ-C30: European Organization for the Research and 
Treatment of Cancer Quality of Life Questionnaire core 30 items; 
QLQ-STO22: European Organization for the Research and 
Treatment of Cancer Quality of Life Questionnaire gastric 
epidermal growth factor receptor 2; HRQOL: Health-related 
Programmed death ligand 1; PFS: Progression-free survival; 
PR: Partial response; RECIST v1.1: Response Evaluation Criteria 
in Solid Tumors version 1.1; SOX: S-1 + oxaliplatin
Pembrolizumab in combination with trastuzumab and 
chemotherapy for HER2-positive advanced gastric 
cancer: KEYNOTE-811 
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